Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?

Abstract : Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and antiestrogenic compounds are very promising drugs for the treatment of MM. Indeed, they inhibit cell proliferation in vitro. They block cell cycle and/or induce apoptosis even in drug-resistant MM cells but not normal B cells. They interfere with survival pathways often deregulated in myelomas. They cooperate with conventional drugs to enhance apoptosis or to overcome resistance. In vivo, they act also on tumoral angiogenesis in xenograft models. As a whole, they possess all the criteria which render them attractive for a new therapeutic strategy. Importantly, they are well-tolerated at the doses tested in vitro or in vivo, encouraging the rapid onset of critical trials.
Type de document :
Article dans une revue
Liste complète des métadonnées

Littérature citée [39 références]  Voir  Masquer  Télécharger

https://hal-normandie-univ.archives-ouvertes.fr/hal-01762023
Contributeur : Université Normandie <>
Soumis le : mercredi 24 juillet 2019 - 15:13:35
Dernière modification le : jeudi 25 juillet 2019 - 01:17:31

Fichier

b_sola.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Licence


Distributed under a Creative Commons Paternité 4.0 International License

Identifiants

Collections

Citation

Brigitte Sola, Jack-Michel Renoir. Estrogenic or Antiestrogenic Therapies for Multiple Myeloma?. Molecular Cancer, BioMed Central, 2007, 6 (1), pp.59. ⟨10.1186/1476-4598-6-59⟩. ⟨hal-01762023⟩

Partager

Métriques

Consultations de la notice

59

Téléchargements de fichiers

29